OOIR: Observatory of International Research

Papers

(The TQCC of Altex-Alternatives to Animal Experimentation is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Alternative Methods in Science: Towards Fluidic Systems	66
Application of high-throughput transcriptomics for mechanism-based biological read-across of short-chain carboxylic acid analogues of valproic acid_suppl1	38
Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo_suppl1	35
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl1	27
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl5	24
Sensitivity analysis and quality indicators for an in vitro oral irritation assay	13
Animal research ethics as interaction of research ethics, animal ethics, and (animal protection) law	12
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency	11
The effect of surfactants and film-forming polymers on pulmonary surfactant function measured in vitro is dose rate dependent_suppl	11
Validation of an Endopep-suspension immunoassay for the diagnostics of human botulism_suppl	11
Off to a good start? Review of the predictivity of reactivity methods modelling the molecular initiating event of skin sensitization	9
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment_suppl4	9
Technical framework for enabling high-quality measurements in new approach methodologies (NAMs)	9
Validation of the monocyte activation test with three therapeutic monoclonal antibodies	9
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment	8
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A	8
REACH out-numbered! The future of REACH and animal numbers	8
Predicting Acute Oral Toxicity Using AcutoX: An Animal Product-Free and Metabolically Relevant Human Cell-Based Test	8
Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing	8
Microphysiological endothelial models to characterize subcutaneous drug absorption_suppl	7
Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study	7
The long way from raw data to NAM-based information: Overview on data layers and processing steps	7
E-validation – Unleashing AI for validation	7
Developing a global education hub for animal-free innovation_suppl	7
Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing	7

Beyond Animal Testing Index: Benchmarking tool for a world beyond animal testing_suppl4	7
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology	6
Protectiveness of NAM-based hazard assessment – which testing scope is required?_suppl1	6
3Rs: Progress or a fig leaf?	6
Exploring the synergy of CRISPR and microphysiological systems	6
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop	6
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations	6
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl3	6
Non-animal approaches – Concept, validation, and regulatory acceptance: The fourth Asian Congress of Alternatives to Animal Experiments (4ACAAE) and the seventh Annual Meeting of the Society for Alter	6
A human osteoarthritis mimicking goat cartilage explant-based disease model for drug screening_suppl	6
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay	5
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl6	5
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting_suppl1	5
In vitro-based prediction of human plasma concentrations of food-related compounds_suppl1	5
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl3	5
Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity	5
The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States	5
Designing a national strategy to enable human-relevant research in India: A multistakeholder roundtable meeting report	5
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl2	5
Investigation of the publication rate of recent research projects using non-human primates in France	5
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data	5
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl4	4
Role of standards and funding in accelerating the development and use of microphysiological systems	4
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	4
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays_suppl	4
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl1	4
Women in Alternatives	4
Assessment of developmental neurotoxicology-associated alterations in neuronal architecture and function using Caenorhabditis elegans_suppl	4
Material-mediated pyrogens in medical devices: Myth or reality?_suppl2	4
Transition to animal-free science: Phasing out animal experiments, phasing in innovation	4
A path forward advancing microphysiological systems	4
ALTEX Proceedings TIERethik Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	4
From cellular perturbation to probabilistic risk assessments	4
Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways	4
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop_suppl	4
Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells_suppl2	3
How to formulate hypotheses and IATA to support grouping and read-across of nanoforms	3
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl7	3
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis_suppl1	3
Human relevant frontiers in drug safety and efficacy	3
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl6	3
Identifying candidate reference chemicals for in vitro testing of the retinoid pathway for predictive developmental toxicity_suppl	3
Comparative evaluation of rat and human in vitro assays for evaluation of thyroid toxicity_suppl1	3
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study_suppl1	3
The SCAHT Adverse Outcome Pathway (AOP)_HUB: A hands-on platform for information exchange, sharing, and developing AOPs	3
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting	2
Proceedings of a workshop to address animal methods bias in scientific publishing_suppl	2
The need for epigenotoxicity testing	2
Open-source human skin model with an in vivo-like barrier for drug testing_suppl	2
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl1	2

Phasing in human-relevant science: Why the UK’s roadmap matters – and how to make it work	2
Virtual control groups in non-clinical toxicology – A replicability challenge	2
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl2	2
Second scientific sessions and international conference of the Society for Alternatives to Animal Testing in Sri Lanka (SAAT-SL)	2
Next-generation risk assessment of chemicals – Rolling out a human-centric testing strategy to drive 3R implementation: The RISK-HUNT3R project perspective	2
Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment	2
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A_suppl	2
Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations_suppl1	2
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides_suppl2	2
Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment	2
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare	2
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl2	2
Micro-replace systems	2
Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl2	2
Bridging the gap in chemical risk assessment: Leveraging metabolite similarity for enhanced read-across applications	2
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl2	2